Glaxo Wellcome - EU prohibits drug-pricing policy

被引：0

|

作者：

不详

机构：

来源：

CHEMISTRY & INDUSTRY | 1999年 / 15期

关键词：

D O I：

暂无

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

引用

下载

收藏

页码：575 / 575

页数：1

相关论文

共 50 条

[11] Welsh technology applicable to antiviral drug discovery licensed to Glaxo Wellcome
不详
DRUG NEWS & PERSPECTIVES, 1999, 12 (06) : 369 - 369
[12] Glaxo Wellcome withdraws drug - Raxar/Vaxar pulled from the market
Fox, S
GENETIC ENGINEERING NEWS, 1999, 19 (20): : 20 - +
[13] A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada
不详
CANADIAN JOURNAL OF CARDIOLOGY, 1997, 13 (01) : 33 - 38
[14] The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs
Kwon, Hye-Young
Kim, Hyungmin
Godman, Brian
Reich, Michael R.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 1007 - 1014
[15] DRUG-INDUSTRY CONSOLIDATION GLAXO MAKES 15-BILLION-DOLLAR BID FOR WELLCOME
LAYMAN, P
CHEMICAL & ENGINEERING NEWS, 1995, 73 (05) : 6 - 7
[16] Bristol-Myers Squibb vs. Glaxo Wellcome AIDS: The new drug war
Smith, L
FORTUNE, 1998, 137 (08) : 60 - 60
[17] New NHI Drug-pricing System in Japan: Incentives for R&D and Budget Neutrality
Naohiko Wakutsu
Hiroshi Nakamura
International Journal of Economic Policy Studies, 2015, 10 (1) : 1 - 12
[18] Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform
Robinson, James C.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (22): : 2017 - 2019
[19] Washington - Drug-pricing "powder keg" stirs up US health-care politics
Greenberg, DS
LANCET, 2000, 355 (9198): : 125 - 125
[20] THE IMPACT OF GENERIC DRUG POLICY ON DRUG PRICING
Lee, B.
Garay, O. U.
Goldhaber-Fiebert, J.
Wilson, L. S.
VALUE IN HEALTH, 2013, 16 (03) : A11 - A11

← 1 2 3 4 5 →